Jefferies Sees More Upside for Regeneron Pharma (REGN)

Jefferies made positive comments Regeneron Pharma (NASDAQ: REGN) Friday, saying the Street is giving the company little credit for its pipleline.

The firm comments, "investors have focused recently on the early success of the Eylea launch which has led to robust expectations on peak sales pot'l of Eylea. However, we believe REGN share price incorporates little valuation for REGN's pipeline specifically REGN727 (hypercholesterolemia). While we await full Ph II data and possibly Ph III trial design to incl REGN727 estimates, we est the program could be valued btwn $19-33/sh on a risk-adjusted basis.

Jefferies reiterated their Buy rating and $127 price target.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $106.20 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
• Premier Financial Corp. (PFC) PT Raised to $22 at Piper Sandler